Charles River Laboratories Director James C. Foster Executes $8.4M Option Exercise & Sale Under 10b5-1 Plan
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Subscribe to track CRL
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
# Insider Transaction Report: CRL
**Company:** CHARLES RIVER LABORATORIES INTERNATIONAL, INC. ($CRL)
**Insider:** James C. Foster
**Role:** Director
**Transaction Date:** 2026-10-22
### Transaction Summary
- **Type:** Option Exercise & Sale (Rule 10b5-1)
- **Shares Sold:** 24,042 @ $350.00
- **Gross Proceeds:** $8,414,700.00
- **Exercise Cost:** 24,042 @ $244.41 ($5,876,105.22)
- **Net Pre-Tax Value:** $2,538,594.78
- **Direct Shares Remaining:** 31,596
- **Indirect Holdings:** 201,814 shares (via Trusts & GRATs)
Comprehensive Analysis
Executive Summary
On October 22, 2026, James C. Foster, a director of Charles River Laboratories International, Inc. ($CRL), executed an option exercise and disposition of 24,042 shares of common stock at a price of $350.00 per share, generating total gross proceeds of $8,414,700.00.
Transaction Breakdown
-
Derivative Exercise:
- Exercised employee stock options (right to buy) covering 24,042 shares at an exercise price of $244.41 per share (total strike cost: $5,876,105.22).
- The options were originally scheduled to expire on May 27, 2032.
-
Open Market Sale:
- Sold all 24,042 acquired shares at a price of $350.00 per share under transaction code
S. - Net pre-tax cash realized from the spread was $2,538,594.78 ($105.59 per share spread).
- Sold all 24,042 acquired shares at a price of $350.00 per share under transaction code
-
10b5-1 Plan Adoption:
- According to Footnote 1, the exercise and sale were conducted pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on March 6, 2026.
Ownership Structure Post-Transaction
Following these transactions:
- Direct Holdings: 31,596 shares of Common Stock.
- Indirect Holdings: 201,814 shares held across multiple vehicles:
- 2024 GRAT: 5,423 shares
- 2025 GRAT: 10,780 shares
- 2026 GRAT: 20,000 shares
- Trust Held by Spouse: 10,000 shares
- Family / Living Trust: 155,611 shares
Total combined beneficial ownership remains substantial at 233,410 shares.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.